New Book Offers "Practical Solutions" to Big Pharma Woes
A new book by Hedley Rees tackles a litany of pharma industry problems, including “eye-watering drug prices, shortages, litigation over damaging side effects, questionable marketing practices, economic adulteration, consent decrees, counterfeiting, patent games [and] price gouging”.
Rees says we should stop believing that medicines are different to all other products on sale in the market, because they are not. Science is an important component in bringing a medicine to the world, but it takes a healthy dose of engineering skills to get them there too, and the application of those skills is sadly lacking in pharma. The system for producing and supplying a medicine to market should be no different, he says, to an aero-engine, automobile or silicon chip. While the book is “uncompromising on facts and evidence”, it aims to offer a “practical solution” for the pharma industry, says the author. Taming The Big Pharma Monster by Speaking Truth to Power by Hedley Rees is published by Filament (London) on May 28, 2019. More information can be found at the author's website: pharmaflowltd.com
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
